Variant report
Variant | nsv817835 |
---|---|
Chromosome Location | chr19:40132825-40162019 |
allele | n/a |
Outlinks | Ensembl   UCSC |
- TF binding region (count:119)
- CpG islands (count:0)
- Chromatin interactive region (count:2)
- LncRNA region (count:1)
- Mature miRNA region (count: 0)
- miRNA target sites (count:0)
No data |
(count:2 , 50 per page) page:
1
(count:1 , 50 per page) page:
1
No. | lncRNA name | Chromosome Location | lncRNA alias |
---|---|---|---|
1 | lnc-LGALS16-1 | chr19:40132792-40133041 | NONHSAT066318 |
No data |
No data |
Variant related genes | Relation type |
---|---|
LGALS16 | TF binding region |
ENSG00000268243 | TF binding region |
ENSG00000196235 | chromatin interactions |
ENSG00000105193 | chromatin interactions |
No. | Variant name | Chromosome position | Chromatin state | Related regulatory elements | Target genes | Extended variants | Associated traits |
---|---|---|---|---|---|---|---|
1 | rs2270028 | chr19:40132825-40132826 | Enhancers Bivalent Enhancer | TF binding regionlncRNA | 1 gene(s) | LD-proxies of rSNPOverlapped rCNV | mRNA abundance |
2 | rs370540139 | chr19:40132842-40132843 | Enhancers Bivalent Enhancer | lncRNA | n/a | Overlapped CNVs | n/a |
3 | rs537944477 | chr19:40132843-40132844 | Enhancers Bivalent Enhancer | lncRNA | n/a | Overlapped CNVs | n/a |
4 | rs114193401 | chr19:40132900-40132901 | Enhancers Bivalent Enhancer | lncRNA | n/a | Overlapped CNVs | n/a |
5 | rs533816611 | chr19:40132918-40132919 | Enhancers Bivalent Enhancer | lncRNA | n/a | Overlapped CNVs | n/a |
6 | rs190282989 | chr19:40132923-40132924 | Enhancers Bivalent Enhancer | lncRNA | n/a | Overlapped CNVs | n/a |
7 | rs545710048 | chr19:40132941-40132942 | Enhancers Bivalent Enhancer | lncRNA | n/a | Overlapped CNVs | n/a |
8 | rs2270029 | chr19:40133000-40133001 | Enhancers Bivalent Enhancer | lncRNA | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
9 | rs138295341 | chr19:40133002-40133003 | Enhancers | lncRNA | n/a | Overlapped CNVs | n/a |
10 | rs375980020 | chr19:40133009-40133010 | Enhancers | lncRNA | n/a | Overlapped CNVs | n/a |
11 | rs7249348 | chr19:40133069-40133070 | Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
12 | rs537386743 | chr19:40133100-40133101 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
13 | rs549894107 | chr19:40133101-40133102 | Enhancers | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
14 | rs1156815 | chr19:40133192-40133193 | Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
15 | rs532186467 | chr19:40133196-40133197 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
16 | rs181253429 | chr19:40133229-40133230 | Enhancers Weak transcription | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
17 | rs565794200 | chr19:40133323-40133324 | Enhancers Weak transcription | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
18 | rs534200362 | chr19:40133326-40133327 | Enhancers Weak transcription | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
19 | rs78167081 | chr19:40133327-40133328 | Enhancers Weak transcription | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
20 | rs567310296 | chr19:40133386-40133387 | Enhancers Weak transcription | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
21 | rs143304935 | chr19:40133422-40133423 | Enhancers Weak transcription | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
22 | rs556215579 | chr19:40133423-40133424 | Enhancers Weak transcription | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
23 | rs578138065 | chr19:40133426-40133427 | Enhancers Weak transcription | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
24 | rs111752670 | chr19:40133433-40133434 | Enhancers Weak transcription | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
25 | rs1156816 | chr19:40133438-40133439 | Enhancers Weak transcription | TF binding region | 1 gene(s) | LD-proxies of rSNPOverlapped rCNV | mRNA abundance |
26 | rs572606170 | chr19:40133447-40133448 | Enhancers Weak transcription | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
27 | rs185081875 | chr19:40133472-40133473 | Enhancers Weak transcription | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
28 | rs188203530 | chr19:40133490-40133491 | Enhancers Weak transcription | TF binding region | 1 gene(s) | Overlapped CNVs | n/a |
29 | rs16973555 | chr19:40133530-40133531 | Enhancers Weak transcription | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
30 | rs60763119 | chr19:40133563-40133564 | Enhancers Weak transcription | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
31 | rs543570666 | chr19:40133569-40133570 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
32 | rs374755040 | chr19:40133579-40133580 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
33 | rs564801120 | chr19:40133582-40133583 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
34 | rs180996204 | chr19:40133621-40133622 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
35 | rs141972757 | chr19:40133634-40133635 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
36 | rs559494107 | chr19:40133666-40133667 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
37 | rs529975636 | chr19:40133678-40133679 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
38 | rs142879556 | chr19:40133681-40133682 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
39 | rs535076505 | chr19:40133690-40133691 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
40 | rs146264285 | chr19:40133691-40133692 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
41 | rs60962641 | chr19:40133698-40133699 | Weak transcription | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
42 | rs141713665 | chr19:40133732-40133733 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
43 | rs185381635 | chr19:40133737-40133738 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
44 | rs371453651 | chr19:40133756-40133757 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
45 | rs554119989 | chr19:40133781-40133782 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
46 | rs373654637 | chr19:40133796-40133797 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
47 | rs566255562 | chr19:40133835-40133836 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
48 | rs572178585 | chr19:40133935-40133936 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
49 | rs7253489 | chr19:40133955-40133956 | Weak transcription | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
50 | rs6508893 | chr19:40133958-40133959 | Weak transcription | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
Disease | PMID | Source |
---|---|---|
Myelodysplastic syndrome | 17634407 | CNVD |
Acute lymphoblastic leukemia | 22237106 | CNVD |
Chordoma | 21602918 | CNVD |
Ewing''s sarcoma | 21437220 | CNVD |
Glioblastoma multiforme | 21080181 | CNVD |
Chronic lymphocytic leukemia | 21546498 | CNVD |
Cancer | 21637783 | CNVD |
Retinoblastoma | 21504564 | CNVD |
Medulloblastoma | 21979893 | CNVD |
Ovarian cancer | 21720365 | CNVD |
Cancer | 20164919 | CNVD |
Thoracic aortic aneurysm | 21092924 | CNVD |
T-cell prolymphocytic leukemia | 19278963 | CNVD |
Prostate cancer | 18632612 | CNVD |
Autism | 22495311 | CNVD |
Adenoid cystic carcinoma | 18698036 | CNVD |
Ductal carcinoma | 22052326 | CNVD |
Pleomorphic liposarcoma | 18784837 | CNVD |
Congenital nephrotic syndrome | 18421352 | CNVD |
Astrocytoma | 17934521 | CNVD |
Leukemia | 17361228 | CNVD |
Adenoid cystic carcinoma | 17372589 | CNVD |
Breast cancer | 21858162 | CNVD |
Breast cancer | 17603634 | CNVD |
Glioma | 21971842 | CNVD |
Esophageal squamous carcinoma | 21637470 | CNVD |
Endometrial cancer | 22040021 | CNVD |
Astrocytoma | 17387387 | CNVD |
Breast cancer | 21264507 | CNVD |
Oligodendroglial tumors | 17285580 | CNVD |
renal disease | 20603712 | CNVD |
Salivary gland adenoid cystic carcinoma | 17545515 | CNVD |
Disorders of sex development | 21048976 | CNVD |
Ovarian cancer | 22174824 | CNVD |
Breast cancer | 16608533 | CNVD |
Neuroblastoma | 18923191 | CNVD |
Breast cancer | 21364760 | CNVD |
Invasive pancreatic ductal carcinoma | 18765526 | CNVD |
Rhabdomyosarcoma | 16790082 | CNVD |
Chordoma | 18071362 | CNVD |
Urothelial carcinoma | 21177765 | CNVD |
small cell lung cancer | 20016488 | CNVD |
Wilms tumour | 21544195 | CNVD |
Mental retardation | 19951919 | CNVD |
19q13.11 deletion syndrome | 22378287 | CNVD |
Myelofibrosis | 22110671 | CNVD |
Breast cancer | 21045282 | CNVD |
Acute lymphoblastic leukemia | 20067559 | CNVD |
Ovarian neoplasms | 16753589 | CNVD |
Malignant fibrous histiocytomas | 21085701 | CNVD |
Metanephric adenoma | 20802469 | CNVD |
Acute myeloid leukemia | 16864856 | CNVD |
Lung cancer | 21569311 | CNVD |
Bladder cancer | 21909424 | CNVD |
Medulloblastoma | 16783165 | CNVD |
Gastric cancer | 18160780 | CNVD |
Hepatocellular carcinoma | 16750200 | CNVD |
Basal cell lymphoma | 19029149 | CNVD |
Breast cancer | 20409316 | CNVD |
Diffuse large b-cell lymphoma | 19029149 | CNVD |
Multiple myeloma | 16616336 | CNVD |
Renal cell carcinoma | 18765545 | CNVD |
Acute myeloid leukemia | 20729466 | CNVD |
Lung cancer | 18438408 | CNVD |
Breast cancer | 22522925 | CNVD |
No. | Chromosome Location | Chromatin state | Cell line | Tissue |
---|---|---|---|---|
1 | chr19:40131800-40133600 | Enhancers | Pancreatic Islets | Pancreatic Islet |
2 | chr19:40132000-40133400 | Enhancers | HepG2 | liver |
3 | chr19:40132200-40133000 | Bivalent Enhancer | A549 | lung |
4 | chr19:40132600-40133200 | Enhancers | Placenta | Placenta |
5 | chr19:40133200-40151200 | Weak transcription | Placenta | Placenta |
6 | chr19:40146800-40147000 | Flanking Active TSS | H1 BMP4 Derived Trophoblast Cultured Cells | ES cell derived |
7 | chr19:40147000-40147200 | Flanking Bivalent TSS/Enh | H1 BMP4 Derived Trophoblast Cultured Cells | ES cell derived |
8 | chr19:40148600-40149400 | Enhancers | iPS DF 19.11 Cell Line | embryonic stem cell |
9 | chr19:40150600-40151200 | Bivalent Enhancer | GM12878-XiMat | blood |
10 | chr19:40152200-40153000 | Enhancers | Primary T cells from cord blood | blood |
11 | chr19:40161200-40162600 | Enhancers | H9 Cell Line | embryonic stem cell |
12 | chr19:40161200-40162600 | Enhancers | HUES64 Cell Line | embryonic stem cell |
13 | chr19:40161200-40162600 | Enhancers | iPS-20b Cell Line | embryonic stem cell |
14 | chr19:40161200-40162600 | Enhancers | ES-UCSF4 Cell Line | embryonic stem cell |
15 | chr19:40161200-40162800 | Enhancers | ES-I3 Cell Line | embryonic stem cell |
16 | chr19:40161200-40162800 | Enhancers | HUES48 Cell Line | embryonic stem cell |
17 | chr19:40161200-40162800 | Enhancers | HUES6 Cell Line | embryonic stem cell |
18 | chr19:40161200-40162800 | Enhancers | iPS-15b Cell Line | embryonic stem cell |
19 | chr19:40161400-40162600 | Enhancers | H1 Cell Line | embryonic stem cell |
20 | chr19:40161400-40162800 | Enhancers | iPS-18 Cell Line | embryonic stem cell |
21 | chr19:40161800-40162000 | Enhancers | H1 BMP4 Derived Mesendoderm Cultured Cells | ES cell derived |